KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Amortizatization of Intangibles: 2017-2022

Historic Amortizatization of Intangibles for Twist Bioscience (TWST) over the last 5 years, with Sep 2022 value amounting to $1.2 million.

  • Twist Bioscience's Amortizatization of Intangibles rose 13.43% to $1.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $14.2 million, marking a year-over-year increase of 2567.60%. This contributed to the annual value of $5.9 million for FY2023, which is 58.49% down from last year.
  • Twist Bioscience's Amortizatization of Intangibles amounted to $1.2 million in Q3 2022, which was down 91.53% from $13.9 million recorded in Q2 2022.
  • Twist Bioscience's 5-year Amortizatization of Intangibles high stood at $13.9 million for Q2 2022, and its period low was -$472,000 during Q1 2022.
  • Moreover, its 3-year median value for Amortizatization of Intangibles was -$29,000 (2020), whereas its average is $1.3 million.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first plummeted by 1,800.00% in 2021, then soared by 7,512.30% in 2022.
  • Quarterly analysis of 5 years shows Twist Bioscience's Amortizatization of Intangibles stood at $78,000 in 2018, then skyrocketed by 92.31% to $150,000 in 2019, then slumped by 181.33% to -$122,000 in 2020, then tumbled by 160.66% to -$318,000 in 2021, then increased by 13.43% to $1.2 million in 2022.
  • Its Amortizatization of Intangibles stands at $1.2 million for Q3 2022, versus $13.9 million for Q2 2022 and -$472,000 for Q1 2022.